Form 8-K REPLIGEN CORP For: Apr 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Repligen (RGEN) PT Lowered to $940 at Truist Securities
April 29, 2025 4:03 PM EDTTruist Securities analyst Srikripa Devarakonda lowered the price target on Repligen (NASDAQ: RGEN) to $940.00 (from $975.00) while maintaining a Buy rating.
The analyst comments "While near-term investor focus remains on the Eylea tail, REGN continues to deliver growth on top/bottom line... More
Repligen (RGEN) PT Lowered to $914 at Jefferies
April 29, 2025 3:58 PM EDTJefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.
The analyst comments "Bottom line: REGN entered Q1 w/ a fairly negative bias into the print given: 1) we were modeling Eylea to miss HERE given the issues w/ Good Days, its pt assistance... More
Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'
April 29, 2025 2:54 PM EDTJPMorgan analyst Rachel Vatnsdal lowered the price target on Repligen (NASDAQ: RGEN) to $190.00 (from $200.00) while maintaining a Overweight rating.
The analyst comments "Repligen (RGEN) reported a strong top-line and bottom-line 1Q beat while reiterating organic revenue growth for the year. Diving deeper, RGEN revenues of $169M came in above the Street of $164M, reflecting +11% organic growth y/y (vs. Street of +7.9% y/y), leading to adj. EPS of $0.39 (vs. Street of $0.34). RGEN raised its... More
